ultomiri bag anoth posit result ahu
first look result
analyst certif import disclosur see
monday pre-open pre-announc nearli jan revenu shortfal sales/ep expect vs consensu
outlook given model apr sale flat q/q management cite linger legacy-pasc channel drag though
major weak appear dc next-gen ture game gpu like impact china soft believ dc shortfal
tie emerg slowdown dc spend hyperscal digest capac add see ture disappoint reflect nascent next-gen
game ecosystem one-tim inventori charg pull gm anoth drag like mix see turing/dc issu
transitori franchis secur long-term reduc estim price target see nvda uniqu ai-
driven growth thesi intact maintain outperform
correct correct earlier interpret
despit holiday last week full interest develop hcit name acquisit activist
regulatori earn calendar page fill earn gear himss confer
orlando februari well oppenheim annual healthcar confer nyc march uninsur rate tick
high amid higher premium administr chang provis khn
ultomiri bag anoth posit result ahu
alexion report anoth posit phase trial ultomiri inhibitor-nav patient atyp hemolyt urem
syndrom ahu time result well flag compani data present press
releas seem suggest risk/benefit profil line soliri believ ultomiri result could actual better patient
ultomiri trial potenti sicker challeng achiev primari endpoint ultomiri phase complet tma
respons defin hematolog normal improv kidney function present full result phase medic
confer look forward present stay bullish name
sustain growth resourc optim
first look result
report ep consensu slightli higher sale guid ep midpoint street manufactur
cost off-set price realiz ahead plan price increas fx drag increment
above-consensu result off-set flattish y/i ebit construct industri latter saw slower sale growth
higher materi labor freight cost financi product also contribut miss increas provis credit loss
markdown equiti secur outlook assum modest sale increas saw continu deceler total retail machin
sale decemb backlog declin y/i continu aggress buyback spend
share benefit quarter look color forward capit alloc well end-market commentari earn
